Inc. (NARI) has reached a new 52-week high, with its stock price climbing to $79.7, marking a significant milestone for the ...
Inari Medical, Inc. NARI is well-poised for growth on the back of a huge market opportunity for its products and its commitment to understanding the venous system. However, the company’s dependency on ...
Inari Medical (NARI – Research Report) received a Hold rating and price target from William Blair analyst Margaret Kaczor today. The ...
Inari Medical (NASDAQ:NARI – Free Report) had its price target increased by Piper Sandler from $52.00 to $80.00 in a report issued on Tuesday morning,Benzinga reports. The brokerage currently has a ...
On Tuesday, Inari Medical Inc (NARI) stock saw a decline, ending the day at $79.5 which represents a decrease of $-0.05 or -0.06% from the prior close of $79.55. The stock opened at $79.54 and touched ...
Inari Medical (NARI – Research Report) received a Hold rating and price target from BTIG analyst Marie Thibault today. The company’s shares closed today at $79.45. Discover outperforming ...
Inari Medical’s top-line growth is primarily driven by its ClotTriever and FlowTriever products that target patients with venous thromboembolism (VTE) (with significant growth opportunities ...
It delivered a trailing four-quarter average earnings surprise of 24.77%. Inari Medical’s top-line growth is primarily driven by its ClotTriever and FlowTriever products that target patients with ...